FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144443028> ?p ?o ?g. }

• W2144443028 endingPage "620" @default.
• W2144443028 startingPage "610" @default.
• W2144443028 abstract "Indigenous children in high-income countries have a heavy burden of bronchiectasis unrelated to cystic fibrosis. We aimed to establish whether long-term azithromycin reduced pulmonary exacerbations in Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease.Between Nov 12, 2008, and Dec 23, 2010, we enrolled Indigenous Australian, Maori, and Pacific Island children aged 1-8 years with either bronchiectasis or chronic suppurative lung disease into a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Eligible children had had at least one pulmonary exacerbation in the previous 12 months. Children were randomised (1:1 ratio, by computer-generated sequence with permuted block design, stratified by study site and exacerbation frequency [1-2 vs ≥3 episodes in the preceding 12 months]) to receive either azithromycin (30 mg/kg) or placebo once a week for up to 24 months. Allocation concealment was achieved by double-sealed, opaque envelopes; participants, caregivers, and study personnel were masked to assignment until after data analysis. The primary outcome was exacerbation (respiratory episodes treated with antibiotics) rate. Analysis of the primary endpoint was by intention to treat. At enrolment and at their final clinic visits, children had deep nasal swabs collected, which we analysed for antibiotic-resistant bacteria. This study is registered with the Australian New Zealand Clinical Trials Registry; ACTRN12610000383066.45 children were assigned to azithromycin and 44 to placebo. The study was stopped early for feasibility reasons on Dec 31, 2011, thus children received the intervention for 12-24 months. The mean treatment duration was 20·7 months (SD 5·7), with a total of 902 child-months in the azithromycin group and 875 child-months in the placebo group. Compared with the placebo group, children receiving azithromycin had significantly lower exacerbation rates (incidence rate ratio 0·50; 95% CI 0·35-0·71; p<0·0001). However, children in the azithromycin group developed significantly higher carriage of azithromycin-resistant bacteria (19 of 41, 46%) than those receiving placebo (four of 37, 11%; p=0·002). The most common adverse events were non-pulmonary infections (71 of 112 events in the azithromycin group vs 132 of 209 events in the placebo group) and bronchiectasis-related events (episodes or investigations; 22 of 112 events in the azithromycin group vs 48 of 209 events in the placebo group); however, study drugs were well tolerated with no serious adverse events being attributed to the intervention.Once-weekly azithromycin for up to 24 months decreased pulmonary exacerbations in Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease. However, this strategy was also accompanied by increased carriage of azithromycin-resistant bacteria, the clinical consequences of which are uncertain, and will need careful monitoring and further study.National Health and Medical Research Council (Australia) and Health Research Council (New Zealand)." @default.
• W2144443028 created "2016-06-24" @default.
• W2144443028 creator A5000005955 @default.
• W2144443028 creator A5005437428 @default.
• W2144443028 creator A5015755650 @default.
• W2144443028 creator A5028114138 @default.
• W2144443028 creator A5028656852 @default.
• W2144443028 creator A5038509173 @default.
• W2144443028 creator A5041447887 @default.
• W2144443028 creator A5052162112 @default.
• W2144443028 creator A5060978364 @default.
• W2144443028 creator A5062510390 @default.
• W2144443028 creator A5073374688 @default.
• W2144443028 creator A5078902935 @default.
• W2144443028 creator A5079832386 @default.
• W2144443028 creator A5087222566 @default.
• W2144443028 date "2013-10-01" @default.
• W2144443028 modified "2023-10-11" @default.
• W2144443028 title "Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial" @default.
• W2144443028 cites W1530121291 @default.
• W2144443028 cites W1972721846 @default.
• W2144443028 cites W2006589399 @default.
• W2144443028 cites W2026179689 @default.
• W2144443028 cites W2035970549 @default.
• W2144443028 cites W2037017598 @default.
• W2144443028 cites W2046266815 @default.
• W2144443028 cites W2047871172 @default.
• W2144443028 cites W2050552493 @default.
• W2144443028 cites W2055470742 @default.
• W2144443028 cites W2064953183 @default.
• W2144443028 cites W2065041722 @default.
• W2144443028 cites W2078186052 @default.
• W2144443028 cites W2088296346 @default.
• W2144443028 cites W2090648579 @default.
• W2144443028 cites W2092436632 @default.
• W2144443028 cites W2094952607 @default.
• W2144443028 cites W2100059020 @default.
• W2144443028 cites W2103108834 @default.
• W2144443028 cites W2103369931 @default.
• W2144443028 cites W2106209244 @default.
• W2144443028 cites W2108506420 @default.
• W2144443028 cites W2109459450 @default.
• W2144443028 cites W2112041538 @default.
• W2144443028 cites W2112103097 @default.
• W2144443028 cites W2116009283 @default.
• W2144443028 cites W2121543526 @default.
• W2144443028 cites W2126954368 @default.
• W2144443028 cites W2133358040 @default.
• W2144443028 cites W2135085388 @default.
• W2144443028 cites W2141399465 @default.
• W2144443028 cites W2141420062 @default.
• W2144443028 cites W2144368975 @default.
• W2144443028 cites W2145355470 @default.
• W2144443028 cites W2150624189 @default.
• W2144443028 cites W2151869728 @default.
• W2144443028 cites W2156404536 @default.
• W2144443028 cites W2158465327 @default.
• W2144443028 cites W2163467593 @default.
• W2144443028 cites W2163761940 @default.
• W2144443028 cites W2169216429 @default.
• W2144443028 cites W2171812479 @default.
• W2144443028 cites W3180990639 @default.
• W2144443028 cites W4231884096 @default.
• W2144443028 doi "https://doi.org/10.1016/s2213-2600(13)70185-1" @default.
• W2144443028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24461664" @default.
• W2144443028 hasPublicationYear "2013" @default.
• W2144443028 type Work @default.
• W2144443028 sameAs 2144443028 @default.
• W2144443028 citedByCount "147" @default.
• W2144443028 countsByYear W21444430282013 @default.
• W2144443028 countsByYear W21444430282014 @default.
• W2144443028 countsByYear W21444430282015 @default.
• W2144443028 countsByYear W21444430282016 @default.
• W2144443028 countsByYear W21444430282017 @default.
• W2144443028 countsByYear W21444430282018 @default.
• W2144443028 countsByYear W21444430282019 @default.
• W2144443028 countsByYear W21444430282020 @default.
• W2144443028 countsByYear W21444430282021 @default.
• W2144443028 countsByYear W21444430282022 @default.
• W2144443028 countsByYear W21444430282023 @default.
• W2144443028 crossrefType "journal-article" @default.
• W2144443028 hasAuthorship W2144443028A5000005955 @default.
• W2144443028 hasAuthorship W2144443028A5005437428 @default.
• W2144443028 hasAuthorship W2144443028A5015755650 @default.
• W2144443028 hasAuthorship W2144443028A5028114138 @default.
• W2144443028 hasAuthorship W2144443028A5028656852 @default.
• W2144443028 hasAuthorship W2144443028A5038509173 @default.
• W2144443028 hasAuthorship W2144443028A5041447887 @default.
• W2144443028 hasAuthorship W2144443028A5052162112 @default.
• W2144443028 hasAuthorship W2144443028A5060978364 @default.
• W2144443028 hasAuthorship W2144443028A5062510390 @default.
• W2144443028 hasAuthorship W2144443028A5073374688 @default.
• W2144443028 hasAuthorship W2144443028A5078902935 @default.
• W2144443028 hasAuthorship W2144443028A5079832386 @default.
• W2144443028 hasAuthorship W2144443028A5087222566 @default.
• W2144443028 hasConcept C126322002 @default.
• W2144443028 hasConcept C142724271 @default.
• W2144443028 hasConcept C168563851 @default.

• next